This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
biotechnology biotechs medical pharmaceuticals
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
biotechnology biotechs medical pharmaceuticals
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
biotechnology biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
biotechnology biotechs medical pharmaceuticals
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
biotechnology biotechs medical pharmaceuticals
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
biotechnology biotechs medical pharmaceuticals